Condition: Castration-resistant Prostate Cancer · CRPC · Sponsor: Innocrin Pharmaceutical
The goal of this clinical study is to determine the safety, tolerability, pharmacokinetics and activity of Seviteronel, a lyase-selective inhibitor of CYP17, in patients with castration-resistant prostate cancer (CRPC).
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| Urology Centers of Alabama | Homewood, Alabama, United States | — |
| H. Lee Moffitt Cancer and Research Institute | Tampa, Florida, United States | — |
| First Urology, PSC | Jeffersonville, Indiana, United States | — |
| Wichita Urology | Wichita, Kansas, United States | — |
| Urology Cancer Center | Omaha, Nebraska, United States | — |
| Comprehensive Cancer Centers of Nevada | Las Vegas, Nevada, United States | — |
| North Shore Hematology Oncology Associates | East Setauket, New York, United States | — |
| Associated Medical Professionals of NY | Syracuse, New York, United States | — |
| NY Cancer and Blood Specialists | The Bronx, New York, United States | — |
| Duke Cancer Institute at Cary: Medical Oncology | Cary, North Carolina, United States | — |
| Duke University Medical Center | Durham, North Carolina, United States | — |
| Gabrail Cancer Center Research | Canton, Ohio, United States | — |
+ 11 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT02012920